Category: Similar Patents

When signal coordination meets next-generation connectivity, even a subtle protocol shift can reshape how networks handle data traffic. EP3469722B1, assigned to MediaTek Inc., is one such patent, now at the

Some inventions make a brief appearance and fade. Others leave a lasting mark by redefining how a technology is experienced. EP2728089B1, owned by American Wave Machines, falls firmly into that

When airflow design meets styling performance, even a simple attachment can transform an entire appliance category.  EP3119235B1, assigned to Dyson Technology Limited, is a European patent currently subject to provisional

Electropolishing may seem like a niche process, but innovations in this field can quietly influence multiple industries, from aerospace to medical devices. EP4249647A1 is one such patent. This European patent

Under-the-radar patents can shape the future without making headlines. Others, like EP2564403B1, are power technologies that millions now take for granted. This European patent, assigned to Powermat Technologies and currently

In the rapidly advancing field of cardiovascular therapeutics, certain patents stand out for their clinical relevance and scientific depth. EP3536712B1 is one of them. This European patent, held by Regeneron

When glass innovation meets precision chemistry, the result can reshape entire product categories. EP3296274B1, assigned to Corning Incorporated, is a European patent currently under amendment proceedings involving TCL EUROPE SAS.

Some patents quietly support innovation. Others shape entire industries by protecting breakthrough ideas. EP4344633B1 belongs in the second group. Recently, this European patent, owned by Abbott Diabetes Care Inc., has

Lipid nanoparticles (LNPs) have become essential to gene therapy and RNA-based treatments. EP2279254B1 plays a central role in this technology shift. Filed by Arbutus Biopharma, the patent discloses a stable

Some patents unlock niche advances. Others, like European patent EP2590626B1, drive global shifts in vaccine delivery and RNA-based immunization. Assigned to GlaxoSmithKline Biologicals SA, this patent outlines a liposomal, non-viral